The AI engine is offline (last seen Aug 12, 05:02 UTC). Scores are shown as of their timestamps; new theses and refreshes are queued and run the moment it returns.

Macro

Search catalysts, news stories, and pressures, or browse the trust-weighted news feed below.

Home tech energy finance healthcare defense industrial consumer communication utilities real estate raw materials
← back
healthcare · sector mood
2017
year mood +0.10 · -0.35 to +0.30 across 12 mo
Monthly mood
bearish −1 +1 bullish
-0.5 -0.25 0 +0.25 +0.5 Jan Feb Mar Apr May -0.35 Jun Jul Aug Sep Oct Nov Dec +0.30
month values ▾
JanFebMarAprMayJunJulAugSepOctNovDec
+0.00+0.00+0.10+0.10-0.35+0.10+0.20+0.13+0.20+0.20+0.20+0.30

Healthcare sentiment is neutral this month despite the House passing a bill to repeal and replace the Affordable Care Act, as the narrow margin signals significant legislative hurdles ahead. Market reaction has been tempered by the low near-term probability of enactment, with investors focusing on the continued uncertainty rather than immediate operational or regulatory shifts. The broader backdrop of policy volatility supports caution, but no concrete changes have yet altered sector fundamentals.

How this mood is scored ▾
Each day the model reads that day's news for the sector and asks, as someone who owns assets or makes their living in it: how am I feeling this month, and why? The month's mood is that running answer, tied to the specific events driving it (the story shown above). It leans on trusted, higher-impact reporting, and on the prior month when a month is quiet, so one loud headline can't swing it. The read updates daily through the month; once a month ends, its mood is locked. This year is read live from the news the pipeline actually collected (hover a bar for its story count). · last computed Jul 11, 2026
Top healthcare stories of 2017
May
House narrowly passes bill to repeal and replace Affordable Care Act pbs.org →

The American Health Care Act cleared the House by a slim margin, moving Republicans' healthcare overhaul to the Senate, though it later failed to pass there. Hospital and insurer stocks moved on shifting odds of major changes to coverage rules.

Aug
FDA approves Novartis' Kymriah, first CAR-T gene therapy in US fortune.com →

The FDA approved Novartis' Kymriah, the first CAR-T cell therapy for pediatric and young adult patients with relapsed leukemia, marking a transformative shift in cancer treatment. The personalized therapy, priced at $475,000 with an outcomes-based model, signals strong market potential and competitive momentum, as rivals like Gilead prepare to enter the space.